guanabenz has been researched along with Libman-Sacks Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bardin, N; Bourbon, C; Camosseto, V; Chasson, L; Chiche, L; Combes, A; Dalet, A; Gatti, E; Liu, H; Manh, TV; Mendes, A; Perego, J; Pierre, P; Santos, MAS; Spinelli, L | 1 |
| McHugh, J | 1 |
2 other study(ies) available for guanabenz and Libman-Sacks Disease
| Article | Year |
|---|---|
Guanabenz inhibits TLR9 signaling through a pathway that is independent of eIF2α dephosphorylation by the GADD34/PP1c complex.
Topics: Animals; Antihypertensive Agents; Cells, Cultured; Dendritic Cells; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Gene Expression Regulation; Guanabenz; Humans; Liver Diseases; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Protein Phosphatase 1; Toll-Like Receptor 9 | 2018 |
Systemic lupus erythematosus: Antihypertensive drug has dual effects.
Topics: Antihypertensive Agents; Eukaryotic Initiation Factor-2; Guanabenz; Humans; Lupus Erythematosus, Systemic; Toll-Like Receptor 9 | 2018 |